Author: Jaclyn

[January 21, 2024, Morrisville, NC] – Jellatech, a leading biotechnology company revolutionizing the production of bio-identical human collagen through cellular agriculture, is thrilled to announce the successful delivery of its first human Type I collagen sample in December 2024, followed by a second delivery in January 2025. This marks a significant milestone in the company’s mission to provide a consistent, scalable, and ethical supply of high-quality collagen for biomedical applications.

With more samples now available on a monthly basis, Jellatech is accelerating the adoption of human Type I collagen for a wide range of applications, including regenerative medicine, medical aesthetics, tissue engineering, and therapeutic solutions.

“These first deliveries demonstrate the scalability and reliability of our technology,” said Stephanie Michelsen, CEO of Jellatech. “Collagen is a cornerstone biomolecule in healthcare and science, but access to fully functional, human-derived collagen has been a major barrier. Our platform not only addresses this challenge but also sets a new standard for sustainability and ethical sourcing.”

Key Applications and Benefits of Jellatech’s Collagen Platform:

• Regenerative Medicine: Supports tissue regeneration, wound healing, and advancements in organ bioprinting.
• Medical Aesthetics: Offers a sustainable alternative for injectables and dermal fillers, with enhanced integration and durability.
• Therapeutics: Opens new possibilities for drug delivery systems and cell and gene therapy solutions.

Jellatech’s technology utilizes cellular agriculture to produce bio-identical human collagen without relying on animal-derived or donor-sourced materials. By replicating the body’s natural processes, the company delivers a collagen supply that is consistent, reliable, and scalable.

With ongoing sample production and deliveries, Jellatech invites partners in the biomedical and biotechnology sectors to collaborate in unlocking the full potential of human collagen for transformative healthcare solutions.

For inquiries about samples or collaborations, please contact Jellatech at hello@jellatech.com.

[Raleigh, NC] – Jellatech, a pioneering biotechnology company using cellular agriculture to produce bio-identical human collagen, is proud to announce its feature in this month’s Medical Insights newsletter under the section Startups Fuel Medical Aesthetics Innovation. The article highlights Jellatech’s innovative advancements in sustainable, scalable, and ethical collagen production.

Jellatech leverages cell culture techniques to replicate what naturally occurs in our bodies to produce human type I collagen. The company’s platform supports critical biomedical applications, tissue regeneration, injectable aesthetics, cell and gene therapy, and therapeutic solutions. This technology ensures a consistent and reliable collagen supply while addressing sustainability and ethical concerns.

“Currently, human collagen is sourced from cadavers, foreskin, or placenta — methods that are inconsistent, limited in supply, and not ideal for scalability,” said Jellatech CEO Stephanie Michelsen. “Using technology developed for bovine collagen, we pivoted to producing lab-grown human collagen. This approach provides a cleaner, higher-yield, and more cost-effective alternative while eliminating reliance on donor-derived materials.”

Michelsen further highlighted the diverse potential of human collagen:

• Medical Aesthetics: Practitioners can use it in injectables and dermal fillers, offering better integration and longer-lasting results compared to hyaluronic acid.
• Regenerative Medicine: Critical for tissue regeneration, wound healing, and even 3D printing of organs.
• Therapeutics and Beyond: Companies working on hair regrowth and other therapies are incorporating Jellatech’s collagen to enhance integration and outcomes.

“With human collagen production currently limited to research settings and exorbitantly expensive, our goal is to make it widely accessible, reduce costs, and deliver better outcomes,” added Michelsen.As featured in Medical Insights, Jellatech is at the forefront of addressing the biomedical industry’s greatest hurdle — a consistent and scalable supply of functional human collagen. Read the full article here: Medical Insights Newsletter.

Morrisville, NC, Dec 3, 2024 –

Jellatech, a biotechnology company revolutionizing health and longevity through sustainable, cell-cultured human collagen and complex proteins, is proud to announce the addition of two esteemed experts to its advisory board: Matthew Kane, an accomplished biotechnology leader, and Dr. Bill Polacheck, a renowned biomedical engineer and cell biologist.

Matthew Kane: Strategic Leadership in Biotechnology
Mr. Kane brings over two decades of biotechnology expertise to Jellatech’s advisory board. Currently serving as CEO of Celyad Oncology, he is a trailblazer in the development of advanced genetic medicines and cellular therapies. Previously, as CEO of Tune Therapeutics, he raised over $100M in financing and advanced groundbreaking epigenetic therapies into clinical studies.

As co-founder and former CEO of Precision BioSciences, Mr. Kane led initiatives that raised over $400M in funding, launched a successful IPO, and formed partnerships exceeding $4.7B in value. His proven ability to build and scale biotech companies will support Jellatech in commercial strategy, licensing, and advancing its therapeutic applications.

Dr. Bill Polacheck: Innovator in Biomechanics and Human Tissue Modeling
Dr. Polacheck is an Assistant Professor in the Joint Department of Biomedical Engineering at UNC and NC State and in Cell Biology and Physiology at the UNC School of Medicine. His pioneering research bridges molecular cell biology and mechanical engineering to recreate biomimetic tissue environments.

With a Ph.D. in Mechanical Engineering from M.I.T. and a wealth of experience at Boston University and Harvard University, Dr. Polacheck’s contributions have been recognized with prestigious awards, including the American Heart Association Career Development Award. His expertise in biomechanics, extracellular proteins, and 3D microfluidics will accelerate Jellatech’s advancements in human tissue modeling and collagen innovation.

Positioning Jellatech for Growth and Impact
“Matthew and Bill are exceptional leaders in their respective fields, and their combined expertise will be instrumental in driving Jellatech’s mission to transform human health and longevity,” said Stephanie Michelsen, CEO of Jellatech. “Matthew’s strategic vision in building biotech companies and Bill’s groundbreaking research in tissue modeling will guide us as we scale our platform and deliver revolutionary collagen-based solutions to the market.”

Jellatech is poised to leverage these partnerships as it advances its R&D, moves into GLP production, and scales up for commercialization.